NASDAQ:OMER - Omeros Stock Price, Forecast & News

Omeros trades on the NASDAQ under the ticker symbol "OMER."

Omeros Co. (NASDAQ:OMER) posted its quarterly earnings data on Tuesday, November, 12th. The biopharmaceutical company reported ($0.33) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.41) by $0.08. The biopharmaceutical company had revenue of $29.86 million for the quarter, compared to analysts' expectations of $27.19 million. The firm's revenue was up 547.7% on a year-over-year basis. During the same period in the prior year, the company earned ($0.81) earnings per share. View Omeros' Earnings History.

Omeros is scheduled to release their next quarterly earnings announcement on Friday, March 6th 2020. View Earnings Estimates for Omeros.

5 Wall Street analysts have issued 12-month price objectives for Omeros' shares. Their forecasts range from $18.00 to $34.00. On average, they anticipate Omeros' stock price to reach $25.75 in the next year. This suggests a possible upside of 91.7% from the stock's current price. View Analyst Price Targets for Omeros.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Omeros in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Omeros.

Media coverage about OMER stock has been trending negative this week, according to InfoTrie Sentiment. The research group rates the sentiment of press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Omeros earned a media sentiment score of -2.3 on InfoTrie's scale. They also assigned media stories about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the next several days. View News Stories for Omeros.

Some companies that are related to Omeros include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), AbbVie (ABBV), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Allergan (AGN), Mylan (MYL), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), The Medicines (MDCO), Horizon Therapeutics (HZNP), Nektar Therapeutics (NKTR) and Pacira Biosciences (PCRX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Omeros investors own include ACADIA Pharmaceuticals (ACAD), Exelixis (EXEL), Array Biopharma (ARRY), Inovio Pharmaceuticals (INO), Sangamo Therapeutics (SGMO), Ocular Therapeutix (OCUL), Portola Pharmaceuticals (PTLA), Amarin (AMRN), Flexion Therapeutics (FLXN) and NVIDIA (NVDA).

Omeros' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Ingalls & Snyder LLC (9.35%), State Street Corp (2.23%), Stifel Financial Corp (1.72%), UBS Group AG (1.01%), Charles Schwab Investment Management Inc. (0.61%) and Credit Suisse AG (0.43%). Company insiders that own Omeros stock include Marcia S Kelbon, Michael A Jacobsen and Thomas J Cable. View Institutional Ownership Trends for Omeros.

OMER stock was sold by a variety of institutional investors in the last quarter, including Ingalls & Snyder LLC, PNC Financial Services Group Inc., Chicago Equity Partners LLC, Bank of America Corp DE, New York State Common Retirement Fund, California Public Employees Retirement System, First Interstate Bank and Goldman Sachs Group Inc.. View Insider Buying and Selling for Omeros.

OMER stock was bought by a variety of institutional investors in the last quarter, including Monashee Investment Management LLC, Stifel Financial Corp, Jacobs Levy Equity Management Inc., UBS Group AG, State Street Corp, Charles Schwab Investment Management Inc., Capital Impact Advisors LLC and Alberta Investment Management Corp. View Insider Buying and Selling for Omeros.

Shares of OMER can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of OMER stock can currently be purchased for approximately $13.43.

Omeros has a market capitalization of $668.14 million and generates $29.87 million in revenue each year. The biopharmaceutical company earns $-126,760,000.00 in net income (profit) each year or ($2.22) on an earnings per share basis. Omeros employs 236 workers across the globe.View Additional Information About Omeros.

The official website for Omeros is http://www.omeros.com/.

Omeros' mailing address is 201 ELLIOT AVENUE WEST, SEATTLE WA, 98119. The biopharmaceutical company can be reached via phone at 206-676-5000.